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Abstract
Background: Little is known about the relationship between cardiovascular risk, disease and actual use of aspirin in
the community.
Methods: The Measuring Disparities in Chronic Conditions (MDCC) study is a community and health facility-based
survey designed to track disparities in the delivery of health interventions for common chronic diseases. MDCC
includes a survey instrument designed to collect detailed information about aspirin use. In King County, WA
between 2011 and 2012, we surveyed 4633 white, African American, or Hispanic adults (45% home address-based
sample, 55% health facility sample). We examined self-reported counseling on, frequency of use and risks of aspirin
for all respondents. For a subgroup free of CAD or cerebral infarction that underwent physical examination, we
measured 10-year coronary heart disease risk and blood salicylate concentration.
Results: Two in five respondents reported using aspirin routinely while one in five with a history of CAD or cerebral
infarction and without contraindication did not report routine use of aspirin. Women with these conditions used
less aspirin than men (65.0% vs. 76.5%) and reported more health problems that would make aspirin unsafe (29.4%
vs. 21.2%). In a subgroup undergoing phlebotomy a third of respondents with low cardiovascular risk used aspirin
routinely and only 4.6% of all aspirin users had no detectable salicylate in their blood.
Conclusions: In this large urban county where health care delivery should be of high quality, there is insufficient
aspirin use among those with high cardiovascular risk or disease and routine aspirin use by many at low risk.
Further efforts are needed to promote shared-decision making between patients and clinicians as well as inform
the public about appropriate use of routine aspirin to reduce the burden of atherosclerotic vascular disease.
Keywords: Aspirin, Prevention, Coronary disease
Background
Aspirin is among the least expensive and most widely
available of medications yet little is known about how it
is being used. Efforts to reduce the burden of cardiovas-
cular disease, the leading cause of death in the world,
have focused on improving the use of aspirin for individ-
uals at higher risk of atherosclerotic vascular disease
[1,2]. For example, in the United States, the Million
Hearts initiative seeks to prevent one million heart at-
tacks and strokes over 5 years, in part, by promoting
appropriate aspirin therapy and other effective interven-
tions. Data on aspirin use in the community is extremely
limited and has generally focused on select populations
of higher-risk individuals or national surveys [3-5]. Little
information is available on difference in use between
men and women. No methods have been developed to
track the appropriateness of this widely adopted inter-
vention at the local level.
In order to provide high-quality evidence for measuring
local health system performance, we developed a novel
community and health facility-based survey designed to
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track disparities in the delivery of interventions for com-
mon chronic diseases. We used survey questions specific-
ally designed to investigate aspirin use and, for a subgroup
undergoing physical examination, measures of cardiovascu-
lar risk and serum salicylic acid levels to explore the rela-
tionship between reported and detected aspirin use. We
hypothesized that risk-treatment mismatch occurs, with
unnecessary aspirin use among low-risk individuals where
risk may exceed benefit as well as inadequate use for higher
risk individuals and those with established disease. Based
on public perception about heart disease as well as national
guideline recommendations for aspirin prescription, we also
hypothesized that women would receive less aspirin than
men. We piloted this new chronic disease surveillance pro-
gram in Seattle-King County, WA, a relatively wealthy and
well-educated U.S. county where we hypothesized that
health care delivery would be of high quality [6].
Methods
Population studied
The Measuring Disparities in Chronic Conditions Survey
is a community-based survey of chronic disease designed
to investigate variation in adult health and health ser-
vices within a large urban county. The study was de-
signed to address the need for high-quality health data
at the local level by integrating multiple data sources
including multi-mode surveys of county residents (tele-
phone, web, mail, and in person interviews), medical and
pharmacy records, administrative databases, and physical
exam data. The survey included non-institutionalized
white, African American, and Hispanic adults aged 18 or
older living in King County, WA. With over 2 million
inhabitants, King is the thirteenth most populous county
in the United States and encompasses the city of Seattle
as well as suburban and rural areas [6]. We sampled
from both the community using home addresses and
from local health facilities using billing codes for prese-
lected common chronic conditions. Sampling from rep-
resentative health facilities was designed to increase the
number of respondents with chronic conditions above
the prevalence typically found in community sampling.
Analysis
In order to ascertain the use of aspirin for vascular dis-
ease, we compared MDCC survey responses separately
for men and women with and without atherosclerotic
cerebrovascular and coronary artery disease (CAD). Dis-
ease status was determined by the response to survey
questions that asked about a history of coronary heart
disease, coronary artery disease, ischemic heart disease
or blocked arteries, angina, myocardial infarction, heart
attack, coronary stenting, coronary artery bypass graft-
ing, or cerebral infarction (also described as a stroke or
brain attack). We defined disease as an affirmative
response to any of these questions. We defined routine
aspirin use as self-report of taking aspirin daily or every
other day. Statistical analysis was performed using Stata
12 [7]. Approval was obtained from the institutional re-
view board of the University of Washington.
Sensitivity analysis using serum metabolite concentration
To validate the survey’s ability to assess disease risk and
self-reported aspirin use, a subgroup of 250 consecutive
survey respondents was invited to a structured examin-
ation for anthropometry, blood pressure measurement,
ECG and phlebotomy. For the subgroup undergoing
physical examination and without self-reported CAD or
cerebral infarction, we measured cardiovascular risk fac-
tors directly, including blood pressure and cholesterol,
to calculate 10-year risk of coronary heart disease events
using the Framingham risk equation as described by
Wilson et al. [8]. To supplement data on self-reported
use of aspirin for this group, we analyzed an untimed
blood sample for the aspirin metabolite salicylate using
liquid chromatography-mass spectrometry according to
a published method [9]. In formal pharmacokinetic stud-
ies, even at a low 25-mg dose of aspirin, serum salicylate
has a half-life of 1.7 hours. Based on this, we have made
the conservative assumption that salicylate levels follow-
ing ingestion of 81–325 mg of aspirin should be detect-
able for at least 8 hours following ingestion using our
high-sensitivity assay [10]. Supporting this assumption,
respondents with detectable salicylate level had a median
lag of 6.3 hours (range 0.25-21.75) between self-reported
time of ingestion and time of phlebotomy and was un-
detectable in only 5 out of 96 respondents with both a
self-reported time of ingestion and a measured metabol-
ite concentration.
Results
We found that 42% of surveyed respondents used aspirin
routinely (27.8% in the community sample and 51.7%
in the health facility sample). Existing disease (defined
as CAD or cerebral infarction) was reported by 1117
(24.1%) of 4633 respondents (Table 1). Our study was
designed to address the limitations of random popula-
tion sampling by identifying more respondents with
elevated risk than is found in untargeted community
surveys. Supporting this hypothesis, we found only 8.1%
in the community sample had disease compared with
33.6% in the health facility sample. Those with disease
from both samples were older, more frequently male,
and more frequently reported white/Caucasian race.
Overall, 33.5% of respondents without disease reported
routine aspirin use, compared with 72.1% of respondents
with disease (chi-squared p < 0.001) (Table 2). These
proportions were only slightly higher when we restricted
the analysis to those not reporting a reason that made
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aspirin unsafe (39.5% without disease and 83.2% with
disease, not shown). A discussion with a health provider
on the risks and benefits of aspirin to prevent heart at-
tack and stroke was reported by 47.9% of those without
disease and 81.7% of those with disease (chi-squared p <
0.001). A health problem that made aspirin or NSAIDs
unsafe was reported by 15.7% of those without disease
and 24.4% of those with disease (chi-squared p < 0.001).
Use and knowledge of aspirin was associated with sex
of the respondent. Significantly more men than women
Table 1 Demographics for community and health facility samples
No history of CAD or cerebral infarction % History of CAD or cerebral infarction %
Community sample 1,583 91.9 139 8.1
Age, median (IQR) 54 (42–65) 70 (59–79)
Male 654 41.3 80 57.6
White, non-Hispanic 1206 76.2 114 82.0
Black, non-Hispanic 90 5.7 8 5.8
Hispanic 239 15.1 17 12.2
Health facility sample 1933 66.4 978 33.6
Age, median (IQR) 62 (52–71) 68 (60–78)
Male 883 45.7 608 62.2
White, non-Hispanic 1613 83.5 881 90.1
Black, non-Hispanic 138 7.1 38 3.9
Hispanic 96 5.0 25 2.6
Total 3516 75.9 1117 24.1
Age, median (IQR) 59 (48–69) 68 (60–78)
Male 1537 43.7 688 61.6
White, non-Hispanic 2,819 80.2 995 89.08
Black, non-Hispanic 228 6.5 46 4.1
Hispanic 335 9.5 42 3.8















Frequency of aspirin use
Never 562 36.6 110 16.0 938 47.5 119 27.7 1,500 42.7 229 20.5
Less than once a week 182 11.9 15 2.2 219 11.1 16 3.7 401 11.4 31 2.8
At least once a week 42 2.7 4 0.6 60 3.0 5 1.2 102 2.9 9 0.8
Every other day 30 2.0 15 2.2 30 1.5 3 0.7 60 1.7 18 1.6
Every day 566 36.9 511 74.3 552 27.9 276 64.3 1,119 31.8 787 70.5
Don’t know or declined to
respond
23 1.5 33 4.8 20 1.0 10 2.3 333 9.6 4 3.9
Risks and benefits of aspirin to prevent heart attack or stroke ever discussed with you
No 708 46.1 115 16.7 1114 56.4 89 20.8 1823 51.9 204 18.3
Yes 825 53.7 573 83.3 859 43.5 339 79.0 1685 47.9 912 81.7
Don’t know or declined to
respond
4 0.3 0 0 4 0.2 1 0.2 8 0.2 1 0.01
Health problem that make aspirin or NSAIDs unsafe
No 1205 78.4 508 73.8 1459 73.8 294 68.5 2665 75.8 802 71.8
Yes 195 12.7 146 21.2 356 18.0 126 29.4 551 15.7 272 24.4
Don’t know or declined to
respond
137 8.9 34 4.9 162 8.2 9 2.1 300 8.5 43 3.9
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reported use both among those with and without disease
(76.5% vs. 65.0% and 38.9% vs. 29.4% respectively, all p
< .05) (Table 2). Men were more likely than women to
report a discussion of risks and benefits among those
without disease (53.7% vs. 43.5%) but not among those
with disease. Reporting a health problem that made as-
pirin or NSAIDs unsafe was more common for women
than men among those with and without disease (29.4%
vs. 21.2% and 18.0% vs. 12.7%, respectively).
Reasons and risks for aspirin use were also explored
using survey questions designed to capture the main in-
dication for treatment and its safety. Among those
reporting routine aspirin use, the most common reason
for using aspirin was for the purpose of lowering the
chance of heart attack or stroke, cited by 697 of 1178
(59.2%) without disease compared with 495 of 802
(61.7%) with disease. Relief of pain was infrequently
cited as the main reason for routine aspirin use (59 of
1178 (5.0%) among those without disease and 16 of 802
(2.0%) with disease). When respondents were asked to
identify reasons that aspirin or non-steroidal anti-
inflammatory medications were unsafe for them (and
allowed to select multiple answers), those without dis-
ease were most likely to report either a stomach or
gastrointestinal condition (139 of 576 (24.1%)) or use of
another blood thinning medication (131 of 576 (22.7%)).
Among respondents with disease, the most common
reasons was most likely to be use of another blood thin-
ning medication (123 of 288 (42.7%)). Allergy (34 of 576
(5.9%) with disease and 12 of 288 (4.2%) without disease)
and history of bleeding events (27 of 288 (5.9%) with
disease and 56 of 576 (9.7%) without disease) were much
less commonly reported reasons for avoiding the use of
aspirin or non-steroidal anti-inflammatory medications.
Of note, routine aspirin use occurred in both groups
even when there was report of a health problem that
made the use of aspirin or NSAIDS unsafe (used by 119
of 551 (21.6%) without disease, despite contraindica-
tions, and by 134 of 272 (49.3%) with disease, despite
contraindications).
Aspirin dose was similar among those with and with-
out disease even though evidence for higher-dose aspirin
is limited. A dose between 80–100 mg was reported by
893 of 1337 (66.8%) with and 516 of 783 (65.9%) without
disease while a dose between 300–350 mg was reported
by 246 of 1337 (18.4%) with and 207 of 783 (26.4%)
without disease. No significant difference in dose was
seen by sex.
Sensitivity analysis
To better understand clinical risk among those who are
disease-free, we calculated the 10-year CHD risk (by
Framingham equation) for the subgroup that underwent
physical examination with phlebotomy. Demographics,
cardiovascular risk and aspirin use for this group are
shown in Table 3. Routine aspirin use was similar among
individuals with both high and low CHD risk (11 of 24
(45.8%) for those with ≥10% risk vs. 55 of 160 (34.4%)
for those with <10% risk, chi squared p = 0.3). These
proportions did not differ significantly when we re-
stricted our analysis to those not reporting a health
condition that made aspirin unsafe. Furthermore, the
proportion reporting a discussion with a health pro-
vider on the risks and benefits of aspirin or a condition
that made aspirin unsafe did not differ significantly by
cardiovascular risk and was similar to rates seen in the
entire study population.
Serum salicylate had a very wide range with a median
detected concentration of 217 ng/ml and interquartile
range 44–1415 ng/ml. Serum salicylate was not detected
in 5 of the 101 (4.6%) respondents reporting routine
aspirin use but was detected in 59 of the 112 (52.7%) re-
spondents reporting no routine aspirin use (Table 4).
Low concentrations of serum salicylate below 100 ng/ml
have been found among many healthy subjects not using
aspirin [11,12]. To address this, we identified a threshold
concentration based on the receiver-operating curve for
salicylate when self-reported use of routine aspirin was
the gold standard. Salicylate concentration >125 ng/ml
correctly classified 83% of self-reported aspirin use (74%
sensitive and 91% specific for routine use). Despite the
suggestion of a positive correlation, salicylate concentra-
tion was not significantly associated with calculated
coronary heart disease risk in this population (p = 0.6)
(Figure 1).
Discussion
In this community-based survey, we found that over
40% of respondents used aspirin routinely. However use
was not routine for many most likely to receive a benefit
from aspirin therapy. For example, one in five with a his-
tory of CAD or cerebral infarction and no contraindica-
tion to aspirin did not use routine aspirin. Furthermore,
half of subjects without disease and 18% with disease
said they had never been told the risks and benefits of
aspirin. Women with CAD or cerebral infarction were
less likely than men to use aspirin routinely and more
likely to report a health problem that would make as-
pirin unsafe.
Among a smaller subgroup undergoing precise meas-
urement of cardiovascular risk, more than half at high
risk for developing CAD did not use routine aspirin. A
third of respondents with low cardiovascular risk used
aspirin routinely. Of those who did report routine aspirin
use, only 5% had no detectable salicylate in their blood, a
metabolite that should have been present among daily users
of aspirin. This suggests that self-report as obtained in this
survey is a reasonable though imperfect measure of actual
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aspirin use. The reason for disagreement between self-
report and serum level is unclear and suggests a difference
in salicylate clearance or the accuracy of self-report for a
small subset of respondents.
Prior data has suggested that aspirin is used routinely
by only 30-60% of individuals who self-report a history
of heart disease [3]. Our study found a slightly higher
rate of reported use among those with disease. One
study has reported a population-based estimate of as-
pirin use and found one in five of all adults took aspirin
routinely [5]. Similarly, the REGARDS study found
31.5% of individuals free of CHD and stroke reporting
use of aspirin [13]. We found over a quarter of adults
used routine aspirin in our community sample but, after
considering objectively measured cardiovascular risk,
use was closer to 35% among individuals with low car-
diovascular risk and 45% among individuals with high
risk. Our results provide additional evidence that the de-
cision to routinely use aspirin among healthy adults is
not well-informed by their actual risk of cardiovascular
disease.
The risk assessment and decision-making needed for
appropriate use of aspirin are complex. Clinical trials
have shown that aspirin has a protective effect for many
people with an elevated risk for cardiovascular events
[14-16]. However, a recent meta-analysis of primary pre-
vention trials shows that nonfatal myocardial infarction,
but not stroke or death, was reduced (with a number
needed to treat around 150) and only when the study
had a control population incidence of myocardial infarc-
tion over 8% over 10 years [17]. Based on this finding,
the U.S. Preventative Health Task force has recom-
mended that a reasonable risk threshold for considering
the use of aspirin for the primary prevention of cardio-
vascular events is a predicted ≥10% event rate over the
following 10 years [2]. This recommendation has been
complicated by considerable disagreement over the pre-
cise benefits of aspirin as well as the best way to define
the higher risk subpopulation most likely to benefit.
Joint U.S. professional society guidelines recommend
consideration of score-based cardiovascular risk while
European guidelines recommend primary prevention as-
pirin only for individuals with hypertension [18,19].
While the role of aspirin in clinical practice continues
to be debated, it remains the most common regularly
taken medication in the United States. This fact reflects
a broad popular acceptance of aspirin as well as its easy
availability and low cost. Despite its ubiquity, the real-
world use of aspirin is not well-understood. Because it is
often obtained over-the-counter and without pharmacy
benefits, databases and electronic health records often
fail to capture aspirin use among the general population.
Other efforts to study aspirin use, such as the REACH
registry, included only higher-risk individuals who vis-
ited outpatient clinics [20]. Further complicating matters
is the use of aspirin for a range of symptoms and dis-
eases beyond reduction of cardiovascular risk, though
our results show routine aspirin use to treat pain to be
much less common than its use for prevention of vascu-
lar disease. Whether aspirin has a role in the prevention
of cancers is not yet clear [21].
What is known about aspirin comes primarily from
self-report during health survey interviews [3,5,22]. The
reliability of self-reported use of aspirin has been
Table 3 Cardiovascular risk factors and aspirin use
among examination subgroup free of disease
N = 184
Age, median (IQR) 59.5 (51–67.5)
Male, n (%) 78 (42.4%)
White, non-hispanic, n (%) 161 (87.5%)
Black, non-hispanic, n (%) 8 (4.4%)
Hispanic, n (%) 15 (8.2%)
Community sample, n (%) 137 (74.5%)
Health facility sample, n (%) 47 (25.5%)
Weight, kg, median (IQR) 79.8 (66.7-92.1)
BMI, kg m2, median (IQR) 26.4 (23.6-30.7)
SBP, mmHg, median (IQR) 118 (111–123)
DBP, mmHg, median (IQR) 68 (61–75)
LDL, median (IQR) 105 (81–129)
HDL, median (IQR) 62 (47–74)
Triglycerides, median (IQR) 117 (84–171)
Current or recent (<1 yr)
tobacco smoker, n (%)
16 (8.7%)
Told you have diabetes by
health professional, n (%)
27 (14.8%)




Ten-year CHD Risk <10%, n (%) 160 (87.0%)
Ten-year CHD Risk ≥10%, n (%) 24 (13.1%)
Routine aspirin use 66 (35.9%)
Risks and benefits of aspirin to
prevent heart attack or stroke
ever discussed with you 92 (50.0%)
Health problem that make aspirin
or NSAIDs unsafe
21 (11.4%)






Any detectable salicylate 96 59
No detectable salicylate 5 53
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questioned [23]. Our measurement of serum salicylate
adds to the understanding of real-world use of aspirin
derived from health surveys. An untimed measurement
of serum salicylate >125 ng/ml was able to correctly classify
most self-reported use of aspirin. However, medication ad-
herence is a complex, recurring, and private behavior for
which no perfect gold-standard exists. It is likely that we
will continue to misclassify medication adherence in health
interview surveys until biomarkers for health interventions
are more widely adopted.
We note that our study population is from a single
county and may not be generalizable to other regions.
Similar to the U.S. as a whole, King County has a me-
dian age of 37 and is approximately 70% white race.
However, income is higher (median household income
of $70,567 in King County vs. $52,762 nationally) [6].
The REGARDS study found lower aspirin use among
those of black race and lower income, suggesting that
our results may not reflect poorer, more racially diverse
counties [13]. Also, cardiovascular outcomes could not
be assessed due to the cross-sectional nature of the
sample, though the Framingham risk score is a well-
validated prediction tool used routinely in clinical settings.
We rely on self-reported history of vascular disease but use
a broad range of questions phrased in lay language (for ex-
ample, cerebral infarction is also described as stroke and
brain attack). A larger sample size for physical examination
was not possible due to funding constraints and, therefore,
we cannot rule out the possibility that real differences went
undetected in this subgroup. Despite these limitations, the
use of anthropometry and biomarkers makes it possible to
consider preventative aspirin use in relationship to actual
rather than perceived or self-reported risk. Because respon-
dents were sampled from both the community and health
facilities, the entire MDCC cohort cannot be taken as a
direct representation of the entire county population. Ra-
ther, the goal of this mixed design was to avoid the selec-
tion bias of prior studies performed in clinics and hospitals
while still identifying an adequate number of respondents
with common chronic diseases. In comparison, large popu-
lation health surveys include relatively few respondents
with chronic diseases. Medical and pharmacy records
collected as part of the MDCC study, currently being ab-
stracted at the time of our analysis, will provide further
clinical details about this cohort.
Conclusion
Our study, based on self-report and serum metabolite
level, confirms insufficient aspirin use among those with
high cardiovascular risk or disease and routine aspirin
use by many despite low risk. These findings are from a
large and well-educated urban county where health care
delivery should be of high quality. Reasonable disagree-
ment over the appropriate clinical use of aspirin for pri-
mary prevention should not prevent significant health
gains from being achieved by improved aspirin use
among individuals at high risk for coronary events. Our
results highlight the need for strategies that better iden-
tify at-risk individuals and promote shared-decision
making between patients and clinicians in order to de-
crease the burden of cardiovascular disease. In addition,
No Use: R-squared=0.01 Routine Use: R-squared=0.11 
P=0.6
Figure 1 Serum salicylic acid concentration among respondents with and without routine aspirin use according to coronary heart
disease risk.
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further effort may be required to inform the public about
risks, benefits, and appropriate use of aspirin.
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